Skip to main content
    T

    Teva Pharma Industries Ltd ADR (TEVA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $42.58
    -1.92 (-4.31%)

    Market Cap: $51.92B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Teva Pharma Industries Ltd ADR (TEVA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Teva Pharma Industries Ltd ADR (TEVA) to earn $2.06 per share in the fiscal year ending Dec 31, 2026, on revenue of $16.78B. Of 13 analysts, 12 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.77, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 92% of the ratings.

    RatingAnalystsShare
    Strong Buy430.8%
    Buy861.5%
    Hold17.7%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 51.9% and revenue estimates rise 3.4%.

    Fiscal year ending Dec 31, 2026
    $2.06
    EPS consensus, revenue $16.78B
    Fiscal year ending Dec 31, 2027
    $3.13
    EPS consensus, revenue $17.35B
    Fiscal year ending Dec 31, 2028
    $3.44
    EPS consensus, revenue $17.99B

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.06$1.98 to $2.3014$16.78B$16.68B to $16.87B11
    Dec 31, 2027$3.13$2.83 to $3.5015$17.35B$16.78B to $17.69B13
    Dec 31, 2028$3.44$3.12 to $3.803$17.99B$17.98B to $18.00B8

    Quarterly Estimates

    The EPS consensus falls from $0.68 for the quarter ending Dec 31, 2026 to $0.61 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.68$0.60 to $0.815$4.34B$4.11B to $4.53B5
    Mar 31, 2027$0.61$0.42 to $0.699$4.07B$4.00B to $4.13B7

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202711

    EPS Trend

    Over the last 30 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.4% from $2.11.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$2.06$2.07$2.11N/AN/AN/A
    Fiscal year ending Dec 31, 2027$3.13$3.13$3.08N/AN/AN/A
    Quarter ending Mar 31, 2027$0.61$0.63$0.63N/AN/AN/A

    Frequently Asked Questions About TEVA

    What is the TEVA stock forecast?

    Consensus analyst estimates put Teva Pharma Industries Ltd ADR's EPS at $2.06 for the fiscal year ending Dec 31, 2026, on revenue of $16.78B. The consensus rating from 13 analysts is Buy.

    How do analysts rate TEVA stock?

    Of 13 analysts covering Teva Pharma Industries Ltd ADR, 4 rate it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from TEVA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $2.06, with estimates from $1.98 to $2.30 from 14 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.13, with estimates from $2.83 to $3.50 from 15 analysts.

    What revenue do analysts expect from Teva Pharma Industries Ltd ADR next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $16.78B, with estimates from $16.68B to $16.87B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $17.35B, with estimates from $16.78B to $17.69B.

    How many analysts cover TEVA?

    13 analysts rate Teva Pharma Industries Ltd ADR stock, and 14 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.